Sort   by:  
 Page size 
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma (CAR-T Metabolites)
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14640 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14634 | MetaboLights
MetabolomicsIFN-γ-driven iNOS induction in macrophages mediates CAR T cell resistance in B cell lymphoma (Glucose Tracer)
Chimeric antigen receptor (CAR) T cell therapies have revolutionized B cell malignancy treatment, but subsets of patients with large B cell lymphoma (LBCL) experience primary resistance or relapse after CAR T cell treatment. To uncover tumor microenvironment (TME)-induced resistance mechanisms, we e...
2026-05-31 | MTBLS14641 | MetaboLights
TranscriptomicsTargeted scRNA-seq and AbSeq of human CAR-T cell infusion product from 28 cancer patients
Immunotherapy using CD19-directed chimeric antigen receptor (CAR)-T cells has shown excellent results for treatment of B-cell leukaemia and lymphoma. To produce CAR-T cells, the patient’s own T cells are isolated from the blood and modified in a laboratory with a genetic vector to express a tumor an...
ORGANISM(S): Homo sapiens 
2023-07-24 | E-MTAB-12407 | biostudies-arrayexpress
ProteomicsInhibition of Furin in CAR macrophages directs them towards a pro-inflammatory phenotype and enhances their anti-tumor activities.
Anti-cancer immunotherapy approaches are increasingly coveted. Chimeric antigen receptor (CAR)-T cell therapy has been shown to be an effective treatment for hematological tumors, but the treatment of solid tumors still lacks effectiveness, due to lower intra-tumor infiltration of CAR-T cells and tu...
ORGANISM(S): Homo sapiens (Human) 
2024-12-12 | PXD058491 | Pride
Proprotein convertases Furin Breast cancer Car macrophage Tumoroids 
UnknownCAR T-Cell Targeting of Macrophage Colony-Stimulating Factor Receptor.
Not available
S-EPMC9323367 | biostudies-literature
GenomicsCAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trial
PRJNA1205748 | ENA
TranscriptomicsTranscription repressor Bach2 is required for pulmonary surfactant homeostasis and alveolar macrophage function.
Pulmonary alveolar proteinosis (PAP) results from a dysfunction of alveolar macrophages (AMs), chiefly due to disruptions in the signaling of granulocyte macrophage colony-stimulating factor (GM-CSF). We found that mice deficient for the B lymphoid transcription repressor BTB and CNC homology 2 (Bac...
ORGANISM(S): Mus musculus 
2014-01-15 | E-GEOD-54050 | biostudies-arrayexpress
GenomicsIPSC-Derived CAR-NK Extracellular Vesicles Remodel Macrophage Immunity and Enhance Tumor Eradication
IPSC-Derived CAR-NK Extracellular Vesicles Remodel Macrophage Immunity and Enhance Tumor Eradication
PRJNA1247458 | ENA
GenomicsA quadrivalent in vivo CAR-macrophage repress solid tumors and overcome tumor heterogeneity through antigen spreading
A quadrivalent in vivo CAR-macrophage repress solid tumors and overcome tumor heterogeneity through antigen spreading
PRJNA1465146 | ENA
Sort   by:  
 Page size